Views: 74 Author: Site Editor Publish Time: 2023-05-15 Origin: Site
Nuobai Pharm., previously known as the Pharm. Division of Sinochem Ningbo/Ninhua Group, started its business in pharmaceuticals in 1987. The company is committed to delivering a one-stop solution for the marketing and sourcing of pharmaceuticals to global clients.
With decades of development, Nuobai Pharm. has established a strong market intelligence and network all over the world, covering various areas such as fine chemicals, pharmaceutical RMs, SMs, intermediates, buffer solutions, linkers, peptides, oligonucleotides, APIs, FDFs, medical consumables, and devices.
Benefiting from rich experience in global GMP & EHS, Nuobai Pharm. is dedicated to providing an overall service that includes supply chain management, DD inspection, 3rd party audit, GMP & EHS training and improvement, as well as global registrations.
The company has three R&D centers located in Ningbo, Taizhou, and Shanghai and one GMP plant, Zhejiang Langhua Pharm. Driven by innovation, reliability, flexibility, and efficiency, Nuobai Pharm. has been involved in the entire life-cycle and CDMO of over 30 new drugs from lab development to commercial launch. Its goal is to create value and deliver competitive and resilient solutions to the global pharmaceuticals industry.
The Dr. Reddy's API business supplies high quality affordable APIs to leading generic formulations manufacturers across the world, enabling them to accelerate access to affordable medicines for patients worldwide. They are the preferred API partner to pharma companies across the US, Europe, Latin America, Japan, China, Korea, and emerging markets.
Their business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules, and highly potent APIs (HPAIs /oncology drugs). This expertise is complemented by their prowess in intellectual property and regulatory affairs, which helps them consistently meet and exceed regulatory standards.
They believe that their strength in innovation, ethical values, and focus on bringing critical, life-saving products early to market secures a unique kind of sustainability for them. Their leadership across global markets is indicative of their strong alignment with their ‘Good Health Can’t Wait’ agenda. While they renewed their goals in 2020 to adapt to changing stakeholder expectations, address climate change, and their resolve to work on material issues, they continued to examine more ways to make an impact. They consulted a larger set of global sustainability and pharmaceutical standards and frameworks, and these findings guided their ESG reviews with the leadership and Board.
Combining a top-down and bottom-up approach, using more tools such as their updated enterprise risk management findings, they set 14 bold and ambitious goals across the ESG dimensions to form their vision for 2030. Each of these goals takes into consideration their critical material topics, the external environment in which they operate, and the business and social impact that they can create. In their core API business, their focus on innovation-led affordability gives their customers access to the most complex active ingredients while maintaining a consistent global quality standard. Their partnerships with leading generic formulation brands to fulfill their drug development needs has also given an edge to their own generics business, enabling them to deliver higher quality at competitive costs.
Lupin, as a leading API manufacturer, supplies to more than 70 countries around the globe. Their superior chemistry skills and commitment to quality and cost-effective manufacturing are supported by their six state-of-the-art and regulatory-approved manufacturing sites, forming the bedrock of their API capabilities.
Their vertically integrated model gives them supply continuity assurance for some of their key generic formulations. This, combined with their operational flexibility, robust business contingency plans through alternate manufacturing sites and multiple API sources, and strong collaboration across the supply chain to meet stringent customer requirements, make Lupin one of the most reliable API partners globally.
Moravek has been committed to the advancement of human health through provision of quality products for research since 1975 and is licensed by the California Department of Health Services (DHS) Food and Drug Branch for the preparation and C-14 labeling of active pharmaceutical ingredients (API) for clinical trials.
All of the over 100 cGMP 14C labeled APIs provided by Moravek were suitable for use in early phase clinical trials in the US and around the world.
With one of the largest radiochemistry groups and state-of-the-art facilities and equipment, Moravek has the expertise and capacity to supply custom radiolabeled APIs that meet release specifications and are on time for your clinical trial.
In addition to cGMP radiosynthesis, solutions offered by Moravek include non-GMP radiosynthesis of carbon-14 and tritium labeled compounds, extensive GLP analytical services and a catalog of over 2,500 highly pure non-GMP radiolabeled compounds for research.
As a small molecule partnership development and manufacturing organisation (PDMO), Sterling Pharma Solutions delivers comprehensive small molecule services spanning pre-clinical development to full commercial manufacturing. The company is widely recognized for its collaborative and transparent team, expertise in complex and hazardous chemistries, and service-focused customer experience, making it a proven and trusted partner to the world's most innovative biotechs and leading pharmaceutical companies.
Sterling has a 50+ year track record of providing a range of complementary services spanning the entire pharmaceutical lifecycle, from early stage discovery to full commercial roll-out. They are capable of supporting their customers' projects from grams to tonnes in-house, in a partnership-led service model that ensures full continuity every step of the way.
Committed to innovation, Sterling partners with leading academic and technological institutions through their Technology and Innovation Programme, to apply emerging technologies in their customers' programs. Most importantly, the company is dedicated to serving as true scientific partners to their customers, providing unrivaled service and support rooted in collaboration and transparency.